Currently, anti‐PD1 immunotherapy has shown excellent antitumor effects.[31] The activation of T cells is inhibited by PD1, whereas tumor progression is promoted by GDF15 through the regulation of the immune microenvironment. The gene discussed is GDF15; the disease is neoplasm.